US › Healthcare

Phio Pharmaceuticals Corp (PHIO)

US · Healthcare · Biotechnology

$0.87-5.94%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.1M

EPS

$-0.36

EPS estimate

$-0.36

EPS came in at -0.36 against a street estimate of -0.36 — a beat of 0.0%.

Key statistics

Market cap

$10.7M

Forward P/E

0.3

P/B

0.94

Book value

$1.08

EPS (TTM)

$-1.29

52-week high

$2.25

52-week low

$0.81

50-day MA

$1.06

200-day MA

$1.10

Beta

0.84

Analyst view

Analysts rate Phio Pharmaceuticals Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $14.00.

Shareholding

Insiders

8.01%

Institutions

10.21%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	1.01%
Geode Capital Management, LLC	0.99%
Vanguard Capital Management, LLC	0.81%
Delaware Management Holdings Inc	0.43%
Cetera Investment Advisers	0.41%
Citadel Advisors Llc	0.41%
Vanguard Fiduciary Trust Co	0.33%
Northern Trust Corp	0.24%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Phio Pharmaceuticals Corp — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.